Associated Papers
The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.
Oubaddou Y et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
Human BRCA pathogenic variants were originated during recent human history.
Li J et al.
Life Science Alliance, 2022
Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
Lavoro A et al.
International Journal of Oncology, 2022
BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia.
Shanmughapriya S et al.
Oncology, 2013
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
Adams S et al.
Cancer Immunology, Immunotherapy : Cii, 2011
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
Janavičius R
The Epma Journal, 2010
Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
Ibrahim SS et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2010
The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.
Peixoto A et al.
Breast Cancer Research and Treatment, 2009
Hereditary ovarian cancer.
Russo A et al.
Critical Reviews in Oncology/hematology, 2009
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM et al.
Familial Cancer, 2009
Helene Hudson Memorial Lectureship CANO 2008.
Benjaminson P
Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2009
Founder mutations in BRCA1 and BRCA2 genes.
Ferla R et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2007
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Einbeigi Z et al.
Familial Cancer, 2007
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2006
High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain).
Infante M et al.
Journal of Human Genetics, 2006
Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.
Weitzel JN et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
Rapid mutation detection in complex genes by heteroduplex analysis with capillary array electrophoresis.
Velasco E et al.
Electrophoresis, 2005
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Bjørge T et al.
British Journal of Cancer, 2004
High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis.
Esteban-Cardeñosa E et al.
Clinical Chemistry, 2004
Molecular analysis of the eighteen most frequent mutations in the BRCA1 gene in 63 Chilean breast cancer families.
Jara L et al.
Biological Research, 2004
Diagnostic criteria for testing for BRCA1 and BRCA2: the experience of the Department of Defense Familial Breast/Ovarian Cancer Research Project.
Fries MH et al.
Military Medicine, 2002
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure.
Spitzer E et al.
International Journal of Cancer, 2000
Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations.
Wagner T et al.
Genomics, 1999
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A et al.
Disease Markers, 1999
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Dørum A et al.
European Journal of Cancer (oxford, England : 1990), 1999